Bayer and Onyx’ Nexavar has priority review status from the FDA.

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals report that an advisory panel to the European Commission issued a positive review of the companies’ liver cancer drug for approval.

The European Committee for Medicinal Products for Human Use recommended that Nexavar be granted marketing authorization for the treatment of patients with hepatocellular carcinoma.

Nexavar is under priority review at the FDA. The drug is already marketed in over 50 countries including the U.S. for the treatment of advanced kidney cancer, according to the firms.

Previous articleBristol-Myers Squibb and Exelixis Ink Four-Year Extension for Cardiovascular and Metabolic Disease Research
Next articlearGentis Signs On LifeCyte to Develop cGMP Facility